Department of Molecular Innovation in Lipidology, National Cerebral and Cardiovascular Center Research Institute, 6-1 Kishibe Shinmachi, Suita, Osaka, 564-8565, Japan.
Laboratory of Clinical Genetics, National Cerebral and Cardiovascular Center, 6-1 Kishibe Shinmachi, Suita, Osaka, 564-8565, Japan.
Atherosclerosis. 2019 Oct;289:101-108. doi: 10.1016/j.atherosclerosis.2019.08.004. Epub 2019 Aug 19.
More than 4970 variants in the low-density lipoprotein receptor (LDLR) gene and 350 variants in the proprotein convertase subtilisin/kexin 9 (PCSK9) gene have been reported in familial hypercholesterolemia (FH) patients. However, the effects of these variants on FH pathophysiology have not been fully clarified. We aimed to update the LDLR and PCSK9 variants in Japanese heterozygous FH (HeFH) patients and annotate their clinical significance for the genetic diagnosis of HeFH.
A genetic analysis of the LDLR and PCSK9 genes was performed in 801 clinically diagnosed HeFH patients. The association of the pathogenic variants with the clinical FH phenotype was examined.
Pathogenic variants in the LDLR and PCSK9 genes were found in 46% (n = 296) and 7.8% (n = 51) of unrelated FH patients (n = 650), respectively. The prevalence of Achilles tendon thickness was low (44%) in patients harbouring PCSK9 pathogenic variants. Furthermore, 17% of unrelated FH patients harboured one of five frequent LDLR pathogenic variants: c.1845+2T > C, c.1012T > A: p.(Cys338Ser), c.1297G > C: p.(Asp433His), c.1702C > G: p.(Leu568Val), and c.2431A > T: p.(Lys811*). Patients harbouring the c.1845+2T > C and c.1702C > G: p.(Leu568Val) variants had significantly lower serum LDL-cholesterol levels and higher serum HDL-cholesterol levels, respectively, compared with those harbouring the other LDLR pathogenic variants. The proportion of LDLR pathogenic variants was higher in patients with a younger age of coronary artery disease (CAD) onset and significantly decreased as the age of CAD onset increased.
This study annotated the clinical significance and characteristics of LDLR and PCSK9 pathogenic variants in Japanese HeFH patients.
在家族性高胆固醇血症(FH)患者中,已报道低密度脂蛋白受体(LDLR)基因中有超过 4970 种变异,前蛋白转化酶枯草溶菌素/柯萨奇蛋白酶 9(PCSK9)基因中有 350 种变异。然而,这些变异对 FH 病理生理学的影响尚未完全阐明。我们旨在更新日本杂合子 FH(HeFH)患者的 LDLR 和 PCSK9 变异,并注释其对 HeFH 遗传诊断的临床意义。
对 801 例临床诊断为 HeFH 的患者进行 LDLR 和 PCSK9 基因的遗传分析。检查致病性变异与临床 FH 表型的关联。
在 650 例无亲缘关系的 FH 患者(n=296)和 51 例(n=51)无亲缘关系的 FH 患者中分别发现 LDLR 和 PCSK9 基因的致病性变异。携带 PCSK9 致病性变异的患者 Achilles 肌腱厚度的患病率较低(44%)。此外,17%的无亲缘关系的 FH 患者携带五个常见 LDLR 致病性变异中的一个:c.1845+2T>C、c.1012T>A:p.(Cys338Ser)、c.1297G>C:p.(Asp433His)、c.1702C>G:p.(Leu568Val)和 c.2431A>T:p.(Lys811*)。与携带其他 LDLR 致病性变异的患者相比,携带 c.1845+2T>C 和 c.1702C>G:p.(Leu568Val)变异的患者血清 LDL-胆固醇水平显著降低,血清 HDL-胆固醇水平显著升高。携带 LDLR 致病性变异的患者的冠心病(CAD)发病年龄较轻,且随着 CAD 发病年龄的增加,该比例显著降低。
本研究注释了日本 HeFH 患者 LDLR 和 PCSK9 致病性变异的临床意义和特征。